DPP4 and heart failure: As to the controversy regarding DPP-4 inhibitors and associated cardiovascular risk, an increased rate of hospitalization for heart failure has been reported [41], whereas no increased rate of cardiovascular events was found in others [42–44], including the very recently published TECOS study with 14,671 patients.